Browsing by Subject "retinopathy of prematurity"

Now showing 1 - 3 of 3
  • Thumbnail Image
    Item
    Promoting vascular repair in the retina: can stem/progenitor cells help?
    (Dove, 2016) Trinh, Thao Le Phuong; Calzi, Sergio Li; Shaw, Lynn C.; Yoder, Mervin C.; Grant, Maria B.; Department of Ophthalmology, IU School of Medicine
    Since its first epidemic in the 1940s, retinopathy of prematurity (ROP) has been a challenging illness in neonatology. Higher than physiological oxygen levels impede the development of the immature retinal neuropil and vasculature. Current treatment regimens include cryotherapy, laser photocoagulation, and anti-VEGF agents. Unfortunately, none of these approaches can rescue the normal retinal vasculature, and each has significant safety concerns. The limitations of these approaches have led to new efforts to understand the pathological characteristics in each phase of ROP and to find a safer and more effective therapeutic approach. In the era of stem cell biology and with the need for new treatments for ROP, this review discusses the possible future use of unique populations of proangiogenic cells for therapeutic revascularization of the preterm retina.
  • Thumbnail Image
    Item
    Prophylactic laser versus continued surveillance after initial bevacizumab treatment for retinopathy of prematurity
    (Science Direct, 2021-05-06) Hong, Gloria J.; Stinnett, Sandra S.; Freedman, Sharon F.; Wallace, David K.; Prakalapakorn, S. Grace; Ophthalmology, School of Medicine
    Guidelines on managing infants after initial anti-vascular endothelial growth factor (VEGF) treatment (eg, bevacizumab) for retinopathy of prematurity (ROP) are limited. We found that following initial bevacizumab treatment for ROP, prophylactically lasering infant eyes before hospital discharge reduced the number and duration of outpatient ROP screening examinations compared with following infants, per current United States (US) ROP screening guidelines.
  • Thumbnail Image
    Item
    Quantitatively comparing weekly changes in retinal vascular characteristics of eyes eventually treated versus not treated for retinopathy of prematurity
    (Elsevier, 2021) Hong, Gloria J.; Koerner, Jagger C.; Weinert, Marguerite C.; Stinnett, Sandra S.; Freedman, Sharon F.; Wallace, David K.; Riggins, J. Wayne; Gallaher, Keith J.; Prakalapakorn, S. Grace; Ophthalmology, School of Medicine
    Purpose To quantitatively compare retinal vascular characteristics over time in eyes eventually treated versus not treated for retinopathy of prematurity (ROP), using ROPtool analysis of narrow-field retinal images. Methods This longitudinal study used prospectively collected narrow-field retinal images of infants screened for ROP, prior to treatment, if needed. Images were analyzed using a methodology that combines quadrant-level measures from several images of the same eye. For the longitudinal analysis, one examination per postmenstrual age (PMA) was included per eye. We compared the following ROPtool indices and their change per week between eyes eventually treated versus not treated for ROP: tortuosity index (TI), dilation index (DI), sum of adjusted indices (SAI), and tortuosity-weighted plus (TWP). Analysis was performed on three levels: eye (mean value/eye), quadrant (highest quadrant value/eye), and blood vessel (highest blood vessel value/eye). Results Of 832 examinations (99 infants), 745 images (89.5%) had 3-4 quadrants analyzable by ROPtool. On the eye level, ROPtool indices differed between eyes eventually treated versus not treated at PMA of 33-35 and 37 weeks for TI, SAI, and TWP, and at PMA of 33-34 and 37 weeks for DI (P ≤ 0.0014), and change per week differed between eyes eventually treated versus not treated only for SAI at PMA of 32 weeks (P < 0.001). Conclusions Quantitative analysis of retinal vascular characteristics using ROPtool can help predict eventual need for treatment for ROP as early as 32 weeks PMA. ROPtool index values were more useful than change in these indices to predict eyes that would eventually need treatment for ROP.